Court rules in favour of Sanofi in FemPatch case:
This article was originally published in Clinica
The Tribunal of the International Chamber of Commerce has ruled in favour of Sanofi in a case brought by the French company against Cygnus. US company Cygnus breached its contract regarding commercialisation of Cygnus' FemPatch, a transdermal hormone replacement therapy patch. The amount of damages is yet to be decided; Sanofi's initial request was for not less than $10 million, plus royalties on future HRT transdermal systems, a sum towards lost market share and the costs of arbitration.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.